ranolazine has been researched along with Kidney Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eworuke, E; Maro, JC; Tobenkin, A; Welch, EC | 1 |
| Blankstein, R; Bui, AH; M Blum, R; Southard, RA | 1 |
| Abdallah, H; Jerling, M | 1 |
1 trial(s) available for ranolazine and Kidney Diseases
| Article | Year |
|---|---|
Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
Topics: Acetanilides; Adolescent; Adult; Aged; Cardiovascular Agents; Cohort Studies; Dealkylation; Delayed-Action Preparations; Electrocardiography; Female; Glomerular Filtration Rate; Half-Life; Humans; Kidney Diseases; Male; Middle Aged; Piperazines; Ranolazine | 2005 |
2 other study(ies) available for ranolazine and Kidney Diseases
| Article | Year |
|---|---|
Use of FDA's Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure.
Topics: Aged; Anticonvulsants; Cardiovascular Agents; Cohort Studies; Humans; Kidney Diseases; Logistic Models; Ranolazine; Risk Assessment; Seizures; United States; United States Food and Drug Administration | 2019 |
Neurologic adverse effects of ranolazine in an elderly patient with renal impairment.
Topics: Acetanilides; Aged, 80 and over; Angina Pectoris; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Nervous System Diseases; Piperazines; Ranolazine | 2013 |